Search
forResearch
5 / 1000+ resultsresearch From Primary MSC Culture of Adipose Tissue to Immortalized Cell Line Producing Cytokines for Potential Use in Regenerative Medicine Therapy or Immunotherapy
The HATMSC1 cell line from fat tissue can produce helpful factors for regenerative and immune therapies.
research Dual effects of human adipose tissue-derived mesenchymal stem cells in human lung adenocarcinoma A549 xenografts and colorectal adenocarcinoma HT-29 xenografts in mice
Stem cells slowed lung tumor growth but increased colon tumor growth in mice.
research The topography of fibrous scaffolds modulates the paracrine function of Ad-MSCs in the regeneration of skin tissues
The shape of fibrous scaffolds can improve how stem cells help heal skin.
research Growth factors IGF-1 and KGF and adipose-derived stem cells promote migration and viability of primary human keratinocytes in an in vitro wound model
IGF-1, KGF, and stem cells help skin cells move and survive, potentially speeding up wound healing.
research THE EFFECT OF HAIR TONIC FROM SECRETOME MESENCHYMAL STEM CELL ON HAIR GROWTH IN HAIR LOSS CASES
A 10% MSC secretome hair tonic best promotes hair growth in alopecia.
Community Join
5 / 1000+ resultscommunity HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community hmi115 is coming. Prepare yourselves for what's coming
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community HMI-115 Australian Phase 1 Trial completed?
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.